KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Retained Earnings (2016 - 2025)

Astrazeneca has reported Retained Earnings over the past 11 years, most recently at $11.0 billion for Q4 2025.

  • Quarterly results put Retained Earnings at $11.0 billion for Q4 2025, up 247.22% from a year ago — trailing twelve months through Dec 2025 was $11.0 billion (up 247.22% YoY), and the annual figure for FY2025 was $11.0 billion, up 247.22%.
  • Retained Earnings for Q4 2025 was $11.0 billion at Astrazeneca, up from $3.2 billion in the prior quarter.
  • Over the last five years, Retained Earnings for AZN hit a ceiling of $11.0 billion in Q4 2025 and a floor of -$574.0 million in Q4 2022.
  • Median Retained Earnings over the past 5 years was $1.7 billion (2021), compared with a mean of $3.4 billion.
  • Biggest five-year swings in Retained Earnings: crashed 133.57% in 2022 and later surged 361.67% in 2023.
  • Astrazeneca's Retained Earnings stood at $1.7 billion in 2021, then crashed by 133.57% to -$574.0 million in 2022, then surged by 361.67% to $1.5 billion in 2023, then skyrocketed by 110.39% to $3.2 billion in 2024, then skyrocketed by 247.22% to $11.0 billion in 2025.
  • The last three reported values for Retained Earnings were $11.0 billion (Q4 2025), $3.2 billion (Q4 2024), and $1.5 billion (Q4 2023) per Business Quant data.